Market Research Media
Cyber Security Market for 2015 -cumulative market valued at $65.5 billion
PRX002 is a monoclonal antibody for the potential treatment of Parkinson's disease and other related synucleinopathies. The drug is the focus of a worldwide collaboration between Prothena and Roche.
in ACAD short and CLDN LONG. Heart Medication $100 + Up From here not going to be $24's LOL
EYES Approved Treatment Healthcare Centers Throughout the US and Europe.
Second Sight's Euro MomentumBy: Dallas SalazarMar. 2, 2015 8:02 AM ET | About: Second Sight Medical Products (EYES)
Health Medical Network
ZIOPHARM Oncology News- Up to five CAR-Ts Are Now excepted To Enter The MD Anderson Cancer Center Clinic in 2015.
MD Anderson President Ron DePinho, M.D., said:
Genetically engineering our patients’ immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today. We believe coupling MD Anderson’s unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, undertighter controland with potentially fewer side effects for patients. This agreement will provide significant resources to fuel its mission of Making Cancer History
have been thinking of becoming a member to Bloomberg Report email . How much does it cost per month?
Investor Business Daily
Mutual Funds Are Buying Up This Cybersecurity Stock
BY ALISSA WILLIAMS, INVESTOR'S BUSINESS DAILY
Its high Accumulation/Distribution Rating can be attributed, in part, to its strong industry group, with top-rated CyberArk Software
Adage Capital Partners Healthcare Fund Bought 20% Of Their Portfolio is ADXS Posted
Adage Capital Partners Healthcare Fund Bought Over $4 Million Shares ADXS cont...
ADAGE CAPITAL PARTNERS GP LLC ..... SC 13G, Advaxis Inc, ADXS, 2015-1-29, 2014-12-15,4,454,604, 0, new position.